Navigation Links
Cytochroma announces appointment of Ulrik Spork to Board of Directors
Date:10/30/2008

MARKHAM, ON, Oct. 30 /PRNewswire/ - Cytochroma today announced the appointment of Ulrik Spork to its Board of Directors. Mr. Spork will represent Novo A/S on the Company's Board and replaces Dr. Soren Schifter, who is leaving Novo A/S. The number of Board members remains unchanged at six members.

"We are very pleased to welcome Ulrik Spork to our board and look forward to drawing on his expertise and experiences as we continue building Cytochroma into a leading CKD-focused specialty pharmaceutical company," stated Alan Lewis, Ph.D., Chairman of Cytochroma's Board of Directors. "We would also like to thank Soren Schifter for his advice to Cytochroma over the years, and wish him well in the future."

Ulrik Spork has significant experience in corporate strategy, business development, M&A, product development, and international marketing. As Senior Partner, he led the establishment of venture investment activities by Novo A/S from its inception in 1999. Prior to the formation of Novo A/S, Mr. Spork was Director of Corporate Development at Novo Nordisk A/S, during which he was involved in that company's strategic planning and managed a number of acquisitions. He holds an MSc in Engineering from the Technical University of Copenhagen and a BSc in International Economics.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company's vitamin D-based therapeutics are designed to safely and effectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in these same patients. For more information, please visit http://www.cytochroma.com.


'/>"/>
SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
2. Cytochroma opens U.S. headquarters in Illinois
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
6. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... and CAMBRIDGE, Mass. ... , Dec. 4, 2016 SystemOne, ... connected diagnostics software platforms for the developing world, ... "Anywhere. Care.™" a reality with its portable and ... entered into a development and license agreement to ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for ... Breast Cancer Symposium. Using molecular test results from tumors with previously documented ...
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
Breaking Biology Technology:
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):